⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
businesswire.com
GMAB
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
globenewswire.com
GMAB
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
globenewswire.com
GTBP
MRNA
IOVA
GMAB
PFE
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
globenewswire.com
GMAB
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
businesswire.com
GMAB
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
globenewswire.com
GMAB
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
businesswire.com
GMAB
INCY
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
businesswire.com
GMAB
INCY
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
globenewswire.com
GMAB
INCY
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
globenewswire.com
GMAB